Autolus Therapeutics shared online summaries for the ASH Annual Meeting, showing data on its T cell therapy candidates.

AUTL · Autolus Therapeutics

The AI's read

Complete blood-related responses suggest the treatment may help people with relapsed or hard-to-treat AL amyloidosis. The evidence comes from early patient groups, and the source gives no patient count or response rate, so the result is encouraging but preliminary.